References
- 1. SHAMLOO, A., DAGRES, N., ARYA, A., & HINDRICKS, G. Atrial fibrillation: A review of modifiable risk factors and preventive strategies. Romanian Journal of Internal Medicine. 2019; 57(2), 99–109.
- 2. REDDY, V., TAHA, W., KUNDUMADAM, S., & KHAN, M. Atrial fibrillation and hyperthyroidism: A literature review. Indian heart journal, 2017; 69(4), 545–550.
- 3. ROSS D.S., BURCH H.B., COOPER D.S. American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016; 26(10):1343–1421.
- 4. HOLLOWELL J.G., STAEHLING N.W., FLANDERS W.D. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): national health and nutrition examination survey (NHANES III). J Clin Endocrinol Metab. 2002; 87(2):489–499.
- 5. GOUDIS C. A., Chronic obstructive pulmonary disease and atrial fibrillation: An unknown relationship. Journal of Cardiology, 2016; 69(5):699–705.
- 6. HANNA IR, HEEKE B, BUSH H, et al. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm. 2006; 3(8):881–886.
- 7. SINGH, S., LOKE, Y.K., ENRIGHT, P., FURBERG, C.D. Pro-arrhythmic and proischaemic effects of inhaled anticholinergic medications. Thorax. 2013; 68:(3) 114–116.
- 8. EMELIA J. BENJAMIN, DANIEL LEVY, SONYA M. VAZIRI. Independent Risk Factors for Atrial Fibrillation in a Population-Based Cohort The Framingham Heart Study. JAMA. 1994; 271(11):840–844.
- 9. KÜHLKAMP V., SCHIRDEWAN A., STANGL K., HOMBERG M., PLOCH M., BECK O.A. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: A randomized, double-blind, placebo-controlled study. Journal of the American College of Cardiology, 2000; 36(1):139–146.